The HKUST Entrepreneurship Center is pleased to congratulate Allegrow Biotech Limited, a startup incubated at HKUST, for winning joint 3rd place in the EQT Impact Challenge Hong Kong 2025.

Organized by the EQT Foundation and South China Morning Post, the EQT Impact Challenge is a platform that recognizes ventures using innovation and entrepreneurship to address pressing social and environmental challenges.

Allegrow Biotech is a Hong Kong-based startup dedicated to advancing drug delivery through its proprietary AimGel artificial cell platform, designed to mimic various cell types in a scalable, synthetic format. The technology supports applications ranging from research tools to therapeutic manufacturing, with a focus on improving immune and stem cell modulation for more accessible and effective cell therapies.

Allegrow’s journey as a biotech venture began at HKUST under the IPIC framework — Ideation, Prototyping, Implementation, and Commercialization. The team first developed its idea through the Dream Builder Program, gained traction via the HKUST One Million Dollar Entrepreneurship Competition, and is now backed by the HKUST Entrepreneurship Fund.

This achievement reflects the strength of Allegrow’s scientific foundation and its commitment to translating academic research into impactful healthcare solutions.

We extend our congratulations to the Allegrow team and to all participants and winners of the EQT Impact Challenge 2025. We also thank the EQT Foundation and South China Morning Post for creating a valuable platform that brings together innovators, investors, and changemakers working to drive positive impact.

To learn more about Allegrow Biotech, visit Allegrow’s LinkedIn page. Stay connected with us at ec.hkust.edu.hk for more success stories from HKUST’s startup community.